Cardiovascular Drugs Practice Questions

Q: Which drug is contraindicated in hypertriglyceridemia?

Cholestyramine. The correct answer is **Cholestyramine**. **Mechanism and Contraindication:** Cholestyramine is a **Bile Acid Sequestrant (BAS)** [2]. It works by binding bile acids in the intestine, preventing their enterohepatic circulation [2]. This depletion of bile acids triggers the liver to convert more cholesterol into bile acids, thereby upregulating LDL receptors and lowering serum LDL. However, the compensatory increase in hepatic cholesterol synthesis is accompanied by a **concomitant increase in VLDL (Very Low-Density Lipoprotein) production** [1]. In patients with pre-existing hypertriglyceridemia, this leads to a significant rise in serum triglyceride (TG) levels, potentially precipitating acute pancreatitis. Therefore, BAS are contraindicated if baseline TG levels are >300 mg/dL [1]. **Analysis of Incorrect Options:** * **A. Fibrates (e.g., Fenofibrate):** These are the **drugs of choice** for severe hypertriglyceridemia. They activate PPAR-α, increasing lipoprotein lipase (LPL) activity and decreasing TG levels. * **B. Simvastatin:** Statins primarily lower LDL but also have a modest TG-lowering effect (10–30%). They are not contraindicated; rather, they are often used in mixed dyslipidemia. * **C. Niacin (Nicotinic Acid):** This is one of the most effective drugs for increasing HDL and is also very effective at lowering triglycerides by inhibiting lipolysis in adipose tissue. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for isolated hypertriglyceridemia:** Fibrates. * **Side effect of Cholestyramine:** Malabsorption of fat-soluble vitamins (A, D, E, K) and drugs like Warfarin or Digoxin. * **Most common side effect of Niacin:** Cutaneous flushing (mediated by Prostaglandin D2; prevented by Aspirin). * **Statin + Fibrate combination:** Increases the risk of **myopathy/rhabdomyolysis** (Gemfibrozil is more risky than Fenofibrate when combined with statins) [1].

Q: Headache is a commonly observed side effect of which anti-anginal drug class?

Nitrates. **Explanation:** **Why Nitrates are the Correct Answer:** Nitrates (e.g., Nitroglycerin, Isosorbide dinitrate) act as prodrugs that release **Nitric Oxide (NO)**. NO activates guanylyl cyclase, increasing cGMP levels, which leads to smooth muscle relaxation. While this effectively causes venodilation (reducing preload) and coronary vasodilation, it also causes significant **vasodilation of the meningeal and extracranial blood vessels**. This rapid stretching of the vessel walls and activation of perivascular pain fibers results in a characteristic throbbing headache, often referred to as a "Nitrate headache." **Analysis of Incorrect Options:** * **Beta blockers (A):** These drugs decrease heart rate and contractility. Their common side effects include bradycardia, fatigue, and bronchospasm, but they are actually used for migraine *prophylaxis*, not as a cause of headache. * **Trimetazidine (C):** A metabolic modulator that shifts myocardial metabolism from fatty acid oxidation to glucose oxidation. It is generally well-tolerated; its unique side effects are Parkinsonian-like symptoms (tremors/rigidity). * **Potassium channel openers (D):** While drugs like Nicorandil can cause headaches due to their nitrate-like moiety, Nitrates are the classic, more "commonly observed" prototype for this side effect in standard pharmacology curricula. **High-Yield Clinical Pearls for NEET-PG:** * **Nitrate Tolerance:** Continuous exposure leads to a loss of efficacy. A "nitrate-free interval" (8–12 hours) is essential to restore sensitivity. * **Monday Disease:** Historically, dynamite factory workers exposed to nitrates during the week developed headaches that disappeared over the weekend (due to tolerance) and returned on Monday. * **Contraindication:** Never co-administer Nitrates with **Sildenafil (PDE-5 inhibitors)**, as this can lead to catastrophic hypotension.

Q: Which of the following is an ultrashort acting beta-blocker devoid of partial agonistic or membrane stabilizing action?

Esmolol. **Explanation** **Esmolol** is the correct answer because it is a cardioselective (β1) antagonist characterized by its **ultrashort duration of action**. It has a half-life of approximately **9 minutes** due to its rapid hydrolysis by **red blood cell esterases**. Crucially, Esmolol lacks intrinsic sympathomimetic activity (partial agonistic action) and membrane stabilizing activity (local anesthetic effect), making it ideal for precise, minute-to-minute titration in acute settings. **Analysis of Incorrect Options:** * **Timolol (B):** A non-selective beta-blocker primarily used in glaucoma. It has a much longer half-life (approx. 4 hours) and is not considered ultrashort acting. * **Atenolol (C):** A cardioselective (β1) blocker with a long half-life (6–7 hours). It is water-soluble and excreted unchanged by the kidneys, unlike the esterase-metabolized Esmolol. * **Pindolol (D):** A non-selective beta-blocker notable for having significant **Intrinsic Sympathomimetic Activity (ISA)**, which the question specifically excludes. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** Esmolol is the only beta-blocker metabolized by **plasma esterases**, making it safe in patients with hepatic or renal impairment. * **Clinical Uses:** Preferred for intraoperative hypertension, supraventricular tachycardia (SVT) during surgery, and aortic dissection (to reduce shear stress). * **Mnemonic:** Remember **"Esmolol is Easy-in, Easy-out"** due to its rapid onset and offset. * **Other Ultrashort Drugs:** Similar to Esmolol, drugs like **Remifentanil** (opioid) and **Clevidipine** (CCB) are also metabolized by esterases.

Q: What is the major clinical use of nimodipine?

Subarachnoid haemorrhage. **Explanation:** **Nimodipine** is a second-generation dihydropyridine calcium channel blocker (CCB). While it shares the basic mechanism of other CCBs (blocking L-type calcium channels), it possesses unique pharmacological properties that dictate its clinical use. **1. Why Subarachnoid Haemorrhage (SAH) is correct:** Nimodipine is highly **lipophilic**, allowing it to readily cross the blood-brain barrier. It has a high affinity for cerebral blood vessels. Following a subarachnoid haemorrhage, patients often suffer from delayed **cerebral vasospasm**, which can lead to secondary ischemic neurological deficits. Nimodipine is the drug of choice to prevent and treat this vasospasm, thereby improving neurological outcomes. **2. Why other options are incorrect:** * **Raynaud’s Phenomenon:** While CCBs like Nifedipine or Amlodipine are used to treat Raynaud’s, Nimodipine is not the preferred agent due to its cerebrovascular specificity. * **Hypertension & Angina:** Although Nimodipine can cause vasodilation, it is significantly less potent than Amlodipine or Nifedipine for systemic hypertension or stable angina. Its short half-life and specific action on cerebral vessels make it unsuitable for routine systemic cardiovascular management. **3. High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** In SAH, Nimodipine is typically given **orally** (or via nasogastric tube). **Caution:** It should never be injected intravenously from a capsule intended for oral use, as this can cause fatal hypotension. * **Mnemonic:** Remember **"Nimo"** for **"Neuro"** (Cerebral specific). * **Other CCB Specifics:** * **Nicardipine:** Often used for hypertensive emergencies. * **Clevidipine:** Ultra-short-acting IV CCB used for acute BP control.

Q: Which of the following drugs used in the management of pulmonary hypertension acts by inhibiting the phosphodiesterase enzyme?

Sildenafil. **Explanation:** **Sildenafil** is the correct answer because it is a potent and selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the pulmonary vasculature, PDE-5 is responsible for the degradation of cyclic Guanosine Monophosphate (cGMP). By inhibiting this enzyme, Sildenafil increases intracellular cGMP levels, which leads to nitric oxide-mediated smooth muscle relaxation and potent vasodilation of the pulmonary arteries, thereby reducing pulmonary artery pressure. **Analysis of Incorrect Options:** * **A. Epoprostenol:** This is a synthetic **Prostacyclin (PGI2) analogue**. It acts by binding to IP receptors to increase cAMP, causing direct vasodilation and inhibition of platelet aggregation. * **B. Bosentan:** This is a dual **Endothelin Receptor Antagonist (ERA)**. It blocks both $ET_A$ and $ET_B$ receptors, preventing the potent vasoconstrictive effects of endothelin-1. * **C. Nifedipine:** This is a **Calcium Channel Blocker (CCB)**. It is used only in a small subset of pulmonary hypertension patients who show a positive "vasoreactivity test" during right heart catheterization. **NEET-PG High-Yield Pearls:** * **Tadalafil** is another PDE-5 inhibitor used in PAH; it has a longer half-life than Sildenafil. * **Riociguat** is a "Soluble Guanylate Cyclase (sGC) Stimulator" often confused with PDE-5 inhibitors; it increases cGMP production directly rather than preventing its breakdown. * **Drug of Choice (DOC):** While treatment is individualized, PDE-5 inhibitors are often first-line oral agents for WHO Group 1 PAH. * **Contraindication:** Never co-administer PDE-5 inhibitors with **Nitrates**, as this can lead to life-threatening hypotension due to synergistic increases in cGMP.

Q: Statins act on which enzyme?

HMG CoA reductase. **Explanation:** **Correct Answer: D. HMG CoA reductase** Statins (HMG-CoA reductase inhibitors) are the first-line drugs for treating hypercholesterolemia. They act by competitively inhibiting the enzyme **3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase**. This enzyme is the **rate-limiting step** in the mevalonate pathway of endogenous cholesterol synthesis. By inhibiting this enzyme, statins decrease intracellular cholesterol levels, which triggers an up-regulation of LDL receptors on hepatocytes, leading to increased clearance of LDL-C from the blood. **Analysis of Incorrect Options:** * **A & B (Acyl CoA synthetase/reductase):** These enzymes are involved in fatty acid metabolism and the activation of long-chain fatty acids, not the primary rate-limiting step of cholesterol synthesis. * **C (HMG CoA synthetase):** This enzyme catalyzes the formation of HMG-CoA from Acetyl-CoA and Acetoacetyl-CoA. While it is part of the pathway, it is not the rate-limiting step and is not the target of statin therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Pleiotropic Effects:** Statins have benefits beyond lipid-lowering, including plaque stabilization, anti-inflammatory effects, and improved endothelial function. * **Timing of Dose:** Since cholesterol synthesis peaks at night, statins with short half-lives (e.g., Lovastatin, Simvastatin) should be taken at **bedtime**. Long-acting statins (Atorvastatin, Rosuvastatin) can be taken any time. * **Adverse Effects:** The most important side effects are **myopathy/rhabdomyolysis** (monitored via CPK levels) and hepatotoxicity (monitored via LFTs). * **Contraindication:** Statins are strictly **contraindicated in pregnancy** (Teratogenic).

Q: Digoxin toxicity may result from the concurrent administration of digoxin with all of the following drugs EXCEPT?

Triamterene. ### Explanation The core concept behind this question is the relationship between **serum potassium levels** and **digoxin toxicity**. Digoxin competes with potassium for binding sites on the Na+/K+-ATPase pump. Therefore, **hypokalemia** (low potassium) increases digoxin binding, leading to toxicity. **1. Why Triamterene is the Correct Answer:** Triamterene is a **potassium-sparing diuretic**. It inhibits sodium reabsorption in the distal tubule and collecting duct without causing potassium loss. By maintaining or slightly increasing serum potassium levels, it prevents the increased binding of digoxin to the ATPase pump, thereby **reducing** the risk of toxicity rather than causing it. **2. Why the Other Options are Incorrect:** * **Quinidine (Option A):** This is a classic drug interaction. Quinidine reduces the renal and extra-renal clearance of digoxin and displaces it from tissue binding sites, significantly increasing plasma digoxin levels. * **Furosemide (Option D) & Hydrochlorothiazide (Option B):** These are loop and thiazide diuretics, respectively. Both are **potassium-wasting diuretics**. They cause hypokalemia, which sensitizes the myocardium to digoxin, precipitating toxicity even if digoxin levels are within the "normal" therapeutic range. **3. Clinical Pearls for NEET-PG:** * **Electrolyte Triad of Digoxin Toxicity:** Hypokalemia, Hypomagnesemia, and Hypercalcemia all predispose a patient to toxicity. * **Most Common Arrhythmia:** Atrial tachycardia with AV block. * **Most Specific Arrhythmia:** Bidirectional Ventricular Tachycardia. * **Management:** Digibind (Digoxin-specific Fab fragments) is the antidote of choice for severe toxicity. * **Other drugs increasing Digoxin levels:** Verapamil, Amiodarone, and Erythromycin.

Q: Which of the following does not result in the release of nitric oxide?

Fenoldopam. ### Explanation **Correct Option: A. Fenoldopam** **Mechanism of Action:** Fenoldopam is a selective **Dopamine-1 (D1) receptor agonist**. It causes vasodilation by stimulating D1 receptors, which increases intracellular **cAMP** (cyclic Adenosine Monophosphate) levels, leading to the relaxation of vascular smooth muscle. Unlike the other drugs listed, its mechanism is entirely independent of the Nitric Oxide (NO)-cGMP pathway. It is primarily used in the management of hypertensive emergencies, especially when renal perfusion needs to be maintained. **Analysis of Incorrect Options:** * **B. Hydralazine:** This is a direct-acting vasodilator. While its exact mechanism is complex, it is known to stimulate the release of **Nitric Oxide** from the vascular endothelium, leading to cGMP-mediated vasodilation of arterioles [1]. * **C. Nitroprusside:** This is a parenteral vasodilator that acts as an **NO donor** [2]. It is non-enzymatically converted to Nitric Oxide in the blood, which activates guanylyl cyclase to increase cGMP, dilating both arterioles and venules. * **D. Nitroglycerin:** This organic nitrate undergoes **enzymatic bioactivation** (via mitochondrial aldehyde dehydrogenase) to release Nitric Oxide, primarily causing venodilation and reducing cardiac preload [2, 3]. **High-Yield Clinical Pearls for NEET-PG:** * **Fenoldopam Unique Property:** It is the only intravenous antihypertensive that improves **renal perfusion** (natriuresis and diuresis) while lowering blood pressure, making it ideal for hypertensive emergencies with renal compromise. * **Nitroprusside Toxicity:** Prolonged infusion can lead to **Cyanide and Thiocyanate toxicity**. The antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Nitrate Tolerance:** Continuous use of Nitroglycerin leads to "tachyphylaxis" due to the depletion of free sulfhydryl groups; a "nitrate-free interval" (8–12 hours) is required to restore sensitivity.

Q: Which is the best inotropic drug for use in right heart failure?

Milrinone. **Explanation:** **Milrinone** is a Phosphodiesterase-3 (PDE3) inhibitor. It increases intracellular cAMP in the myocardium, leading to increased contractility (inotropy). Crucially, it also increases cAMP in vascular smooth muscle, causing systemic and **pulmonary vasodilation** (lusitropy and vasodilation). In right heart failure (RHF), the right ventricle (RV) is often struggling against high pulmonary vascular resistance (PVR). Milrinone is the "best" choice because it provides "Inodilatation"—improving RV contractility while simultaneously decreasing the afterload on the RV by dilating the pulmonary artery. **Analysis of Incorrect Options:** * **Dobutamine:** A $\beta_1$ agonist that increases cardiac output. While it is a potent inotrope, it has less pronounced effects on reducing pulmonary vascular resistance compared to Milrinone and can increase myocardial oxygen demand significantly. * **Digoxin:** A weak inotrope that inhibits Na+/K+ ATPase. It is primarily used for rate control in atrial fibrillation or symptomatic relief in chronic HFrEF, but it is not the drug of choice for acute right heart failure management. * **Dopamine:** At higher doses, it has $\alpha_1$ agonistic effects which can increase systemic and pulmonary vascular resistance, potentially worsening the strain on a failing right ventricle. **High-Yield Clinical Pearls for NEET-PG:** * **"Inodilators":** Milrinone and Levosimendan are categorized as inodilators (Inotrope + Vasodilator). * **Renal Caution:** Milrinone is renally cleared; dosage adjustment is required in renal failure. * **Side Effect:** The most common side effect of Milrinone is hypotension (due to vasodilation) and arrhythmias. * **Mechanism:** PDE3 inhibition $\rightarrow$ $\uparrow$ cAMP $\rightarrow$ $\uparrow$ Calcium influx in heart (contraction) and $\uparrow$ Calcium uptake in smooth muscle (relaxation).

Q: Which of the following is a K+ channel opener?

Minoxidil. **Explanation:** **Mechanism of Action (The Correct Answer):** **Minoxidil** is a potent direct-acting vasodilator that acts as a **Potassium (K+) channel opener**. It works by opening ATP-sensitive K+ channels in the smooth muscle cells of peripheral arterioles. This leads to K+ efflux, causing membrane hyperpolarization, which prevents the opening of voltage-gated calcium channels. The resulting decrease in intracellular calcium leads to smooth muscle relaxation and profound vasodilation. **Analysis of Incorrect Options:** * **A. Nifedipine:** This is a **Dihydropyridine Calcium Channel Blocker (CCB)**. It lowers blood pressure by inhibiting L-type calcium channels in vascular smooth muscle, not by acting on K+ channels. * **C. Enalapril:** This is an **ACE Inhibitor**. It works by inhibiting the Angiotensin-Converting Enzyme, thereby reducing the production of Angiotensin II (a potent vasoconstrictor) and decreasing aldosterone levels. * **D. Atenolol:** This is a **Cardioselective $\beta_1$-blocker**. It reduces blood pressure primarily by decreasing cardiac output and inhibiting renin release from the juxtaglomerular apparatus. **High-Yield Clinical Pearls for NEET-PG:** * **Other K+ Channel Openers:** Nicorandil (used in angina), Diazoxide (used in insulinoma/hypertensive emergencies), and Pinacidil. * **Side Effects of Minoxidil:** It causes significant salt and water retention (often requiring diuretics) and reflex tachycardia (requiring $\beta$-blockers). * **Hypertrichosis:** A unique side effect of Minoxidil is excessive hair growth; hence, it is used topically for treating **Androgenetic Alopecia**. * **Diazoxide** is unique because it also inhibits insulin release, making it useful in treating hypoglycemia due to hyperinsulinism.

Question 1

Which drug is contraindicated in hypertriglyceridemia?

Accepted Answer

Cholestyramine

Answer

Fibrates

Answer

Simvastatin

Answer

Niacin

Question 2

Headache is a commonly observed side effect of which anti-anginal drug class?

Accepted Answer

Nitrates

Answer

Beta blockers

Answer

Trimetazidine

Answer

Potassium channel openers

Question 3

Which of the following is an ultrashort acting beta-blocker devoid of partial agonistic or membrane stabilizing action?

Accepted Answer

Esmolol

Answer

Timolol

Answer

Atenolol

Answer

Pindolol

Question 4

What is the major clinical use of nimodipine?

Accepted Answer

Subarachnoid haemorrhage

Answer

Raynaud's phenomenon

Answer

Hypertension

Answer

Angina

Question 5

Which of the following drugs used in the management of pulmonary hypertension acts by inhibiting the phosphodiesterase enzyme?

Accepted Answer

Sildenafil

Answer

Epoprostenol

Answer

Bosentan

Answer

Nifedipine

Question 6

Statins act on which enzyme?

Accepted Answer

HMG CoA reductase

Answer

Acyl CoA synthetase

Answer

Acyl CoA reductase

Answer

HMG CoA synthetase

Question 7

Digoxin toxicity may result from the concurrent administration of digoxin with all of the following drugs EXCEPT?

Accepted Answer

Triamterene

Answer

Quinidine

Answer

Hydrochlorothiazide

Answer

Furosemide

Question 8

Which of the following does not result in the release of nitric oxide?

Accepted Answer

Fenoldopam

Answer

Hydralazine

Answer

Nitroprusside

Answer

Nitroglycerin

Question 9

Which is the best inotropic drug for use in right heart failure?

Accepted Answer

Milrinone

Answer

Dobutamine

Answer

Digoxin

Answer

Dopamine

Question 10

Which of the following is a K+ channel opener?

Accepted Answer

Minoxidil

Answer

Nifedipine

Answer

Enalapril

Answer

Atenolol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?